The relationship between low muscle mass (LMM) with obesity and hearing loss has been poorly studied. We aimed to investigate the association of LMM and obesity on hearing loss in the general population. A total of 265,792 adults who underwent a hearing test and body composition analyses were included. Pre-sarcopenia was defined as having an appendicular muscle mass index <5.7 kg/m2 for women and <7.0 kg/m2 for men, and obesity as a body mass index ≥25 kg/m2, while pre-sarcopenic obesity was defined as the co-presence of LMM and obesity. Participants were divided into four groups according to the presence of pre-sarcopenia and/or obesity. The prevalence of hearing loss was 1.8% in the control, 2.5% in the pre-sarcopenia alone, 3.0% in the obesity alone, and 6.2% in the pre-sarcopenic obesity group (p < 0.001). Hearing Thresholds were the highest in the pre-sarcopenic obesity group compared with the other three groups. In multivariable-adjusted models, the risk of hearing loss was the highest in the pre-sarcopenic obesity group (odds ratio: 1.30 [95% confidence interval: 1.10–1.56]), followed by the obesity alone (1.20 [1.12–1.28]) and pre-sarcopenia alone (1.19 [1.06–1.34]) group compared with the control group (p < 0.001). Pre-sarcopenic obesity was independently associated with a higher prevalence of hearing loss, supporting pre-sarcopenic obesity itself as a risk for the decline in hearing function.
IgG4-related disease is a fibroinflammatory condition by infiltration of IgG4-positive plasma cells that often presents as a tumorous lesion. This disease can affect nearly every organ system. After the pancreas, the head and neck region is second most common site for presentation of IgG4- related disease such as Mikulicz’s disease, Küttner tumor. The involvement of IgG4-related disease in laryngeal lesions is extremely rare. We have experienced a case of IgG4-related disease with pseudotumor formation in the larynx that is suggestive of malignancy in radiologic findings. But the pathology findings was finally confirmed as IgG4-related disease. Oral treatment with prednisolone was initiated, and the edematous mass reduced in size without permanent functional impairment of vocal fold mobility. We report our experience with a literature review.
Background and Objectives Metabolic syndrome is a medical problem featured by the coexistence of several risk factors such as, heart disease, stroke, and diabetes. The association between metabolic syndrome and incidental paranasal sinusitis has not been definitely proved yet. This study was established to prove if metabolic syndrome might be related to incidental paranasal sinusitis.Subjects and Method Of 5682 patients who had undergone brain MRI for regular checkups between 2011 and 2018 at Kangbuk Samsung Health Care Center, we analyzed 2882 cases with normal sinus and incidental paranasal sinusitis that had been deciphered by specialized radiologists. Data of various components of metabolic syndrome were also used. Multivariable logistic regression analysis was performed to calculate the odds ratio (OR) of having incidental paranasal sinusitis between subjects with metabolic syndrome components and those without.Results Of 2882 patients aged over 18 years (mean age, 51.8±9.47 years; 55.4% male), 353 incidental paranasal sinusitis subjects (232 male with mean age of 51.39±9.27 years and 121 female with mean age of 52.43±9.69 years) were identified. Metabolic syndrome was identified in 554 patients. The adjusted OR of having incidental paranasal sinusitis was 3.03 (95% confidence interval [CI]: 1.58-5.83) in female with metabolic syndrome. In female, the adjusted OR of having incidental paranasal sinusitis was 2.10 (95% CI: 1.20-3.67) in those with low high density lipoprotein (HDL) cholesterol (<50 mg/dL) and 1.83 (95% CI: 1.06-3.16) in those with higher body mass index (BMI) (≥25 kg/m<sup>2</sup>).Conclusion Results of this study suggest that female with metabolic syndrome, low HDL cholesterol, and high BMI have higher risks for incidental paranasal sinusitis.
Background and Objectives A large-scale community-based study of the general population has not been conducted. There have been no studies on the relationship between decreased renal function and the degree of hearing loss. Thus, the purpose was to evaluate the relationship between hearing loss and impaired renal function with a large number of populations.Subjects and Method We performed a cross-sectional population-based cohort study by enrolling 470718 adults, 18 to 80 years old with pure tone audiometry tests who had regular health screening between 2013 and 2018. Hearing loss was defined as a pure-tone average of thresholds at 500, 1000, and 2000 Hz in both right and left ears. Kidney function was evaluated based on eGFR. Chronic kidney disease (CKD) was diagnosed as an eGFR<60 mL/ min/1.73 m². Other predictor variables including noise and age that can affect hearing were also used to evaluate correlation factors.Results Of Participants with CKD, 14.2% had any hearing loss (>25 dB) and 5.0% had above moderate hearing loss (>40 dB). But those with normal kidney function, 2.0% either had any hearing loss and 0.4% had above moderate hearing loss. The odds ratio (OR) of above moderate hearing loss for participants with CKD was 1.51 (95% confidence interval [CI]: 1.15-2.00, <i>p</i>=0.003) but the OR of mild hearing loss for participants with CKD was 0.82 (95% CI: 0.67- 1.02, <i>p</i>=0.073). The result suggested that CKD and above moderate hearing loss were related even after correcting for potential confounders, but had no statistical significance with mild hearing loss.Conclusion Decreased kidney function is associated with above moderate hearing loss.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.